The stereoselective interaction of warfarin and metronidazole in man
- PMID: 934223
- DOI: 10.1056/NEJM197608122950702
The stereoselective interaction of warfarin and metronidazole in man
Abstract
Because of the known interaction of warfarin and disulfiram and the "disulfiram effect" of metronidazole, the interaction with metronidazole of commercial racemic warfarin and its separated enantiomorphs was evaluated in eight normal subjects. Single oral doses of racemate, S(-)-warfarin, and R (+)-warfarin, were administered in the amounts of 1.5, 0.75 and 1.5 mg per kilogram of body weight, respectively, with and without metronidazole, 750 mg by mouth, beginning seven days before the warfarin dose and continuing seven days before the warfarin dose and continuing daily throughout the hypoprothrombinemia. Daily plasma samples were analyzed for warfarin in content and one-stage prothrombin time. A highly significant (P less than 0.01) augmentation of the mean warfarin level and hypoprothrombinemia with metronidazole occurred for racemic and S (-)-warfarin; none occurred with R (+)-warfarin. Thus, the interaction of racemic warfarin and metronidazole is stereoselective and can be lessened or even avoided by use of R (+)-warfarin alone for long-term therapy.
Similar articles
-
Stereoselective interaction of phenylbutazone with [12C/13C]warfarin pseudoracemates in man.J Clin Invest. 1980 Mar;65(3):746-53. doi: 10.1172/JCI109722. J Clin Invest. 1980. PMID: 7354137 Free PMC article.
-
Comparative interaction of cimetidine and ranitidine with racemic warfarin in man.Arch Intern Med. 1984 May;144(5):989-91. Arch Intern Med. 1984. PMID: 6324710 Clinical Trial.
-
Comparative interaction of sulfinpyrazone and phenylbutazone with racemic warfarin: alteration in vivo of free fraction of plasma warfarin.J Pharmacol Exp Ther. 1981 Dec;219(3):691-4. J Pharmacol Exp Ther. 1981. PMID: 7299692
-
Warfarin therapy. 2.N Engl J Med. 1970 Oct 8;283(15):801-3. doi: 10.1056/NEJM197010082831508. N Engl J Med. 1970. PMID: 4917271 Review. No abstract available.
-
Hereditary warfarin resistance.South Med J. 1994 Mar;87(3):407-9. doi: 10.1097/00007611-199403000-00023. South Med J. 1994. PMID: 8134868 Review.
Cited by
-
Anti-anaerobic antimicrobial agents: cefoxitin, cefotetan, clindamycin, and metronidazole.Tex Heart Inst J. 1990;17(2):77-85. Tex Heart Inst J. 1990. PMID: 15227388 Free PMC article. No abstract available.
-
Clinical relevance of pharmacokinetics.Clin Pharmacokinet. 1980 Mar-Apr;5(2):105-36. doi: 10.2165/00003088-198005020-00001. Clin Pharmacokinet. 1980. PMID: 6102499 Review. No abstract available.
-
Interaction of sulphinpyrazone with warfarin.Eur J Clin Pharmacol. 1982;22(4):327-31. doi: 10.1007/BF00548401. Eur J Clin Pharmacol. 1982. PMID: 7106169
-
Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.Curr Clin Pharmacol. 2010 May;5(2):96-114. doi: 10.2174/157488410791110797. Curr Clin Pharmacol. 2010. PMID: 20156156 Free PMC article. Review.
-
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e44S-e88S. doi: 10.1378/chest.11-2292. Chest. 2012. PMID: 22315269 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources